Novo Cure LTD NVCR
We take great care to ensure that the data presented and summarized in this overview for NovoCure Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVCR
View all-
Black Rock Inc. New York, NY12.1MShares$137 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.5MShares$118 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.9MShares$77.8 Million9.53% of portfolio
-
Capital World Investors Los Angeles, CA6.38MShares$71.9 Million0.02% of portfolio
-
State Street Corp Boston, MA2.68MShares$30.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.44MShares$27.5 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.27MShares$25.6 Million0.07% of portfolio
-
Marshall Wace, LLP London, X01.41MShares$15.9 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.37MShares$15.5 Million0.01% of portfolio
-
Quantinno Capital Management LP New York, NY1.37MShares$15.4 Million0.11% of portfolio
Latest Institutional Activity in NVCR
Top Purchases
Top Sells
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Insider Transactions at NVCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,949
-3.54%
|
$35,388
$12.23 P/Share
|
|
Nov 04
2025
|
Christoph Brackmann Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,033
-4.98%
|
$84,396
$12.23 P/Share
|
|
Nov 01
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
168
-0.2%
|
$2,016
$12.81 P/Share
|
|
Nov 01
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
966
-0.28%
|
$11,592
$12.81 P/Share
|
|
Oct 31
2025
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-0.46%
|
$9,024
$12.82 P/Share
|
|
Sep 05
2025
|
Ashley Cordova Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
81,550
+15.71%
|
$978,600
$12.22 P/Share
|
|
Jul 29
2025
|
Christoph Brackmann Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+4.68%
|
$220,000
$11.58 P/Share
|
|
Jun 30
2025
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
833
+0.5%
|
$12,495
$15.13 P/Share
|
|
Jun 30
2025
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
769
+0.44%
|
$11,535
$15.13 P/Share
|
|
Jun 30
2025
|
Ashley Cordova Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
833
+0.23%
|
$12,495
$15.13 P/Share
|
|
Jun 30
2025
|
Asaf Danziger |
BUY
Grant, award, or other acquisition
|
Direct |
833
+0.2%
|
$12,495
$15.13 P/Share
|
|
Jun 30
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
833
+0.24%
|
$12,495
$15.13 P/Share
|
|
Jun 04
2025
|
Kristin Stafford |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+44.01%
|
-
|
|
Jun 04
2025
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+10.82%
|
-
|
|
Jun 04
2025
|
Timothy J Scannell |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+39.42%
|
-
|
|
Jun 04
2025
|
Allyson J Ocean |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+44.01%
|
-
|
|
Jun 04
2025
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+40.02%
|
-
|
|
Jun 04
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
179,426
+34.03%
|
-
|
|
Jun 04
2025
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+5.89%
|
-
|
|
Jun 04
2025
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
11,215
+32.39%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.2M shares |
|---|---|
| Open market or private purchase | 102K shares |
| Open market or private sale | 83.6K shares |
|---|---|
| Payment of exercise price or tax liability | 11.9K shares |